Trial · NCT00786474

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

NCT00786474, Phase 3, Completed, Duke University; results first posted 2016-03-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study). Trials, record NCT00786474. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00786474

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
NCT number: NCT00786474
Status: Completed
Phases: Phase 3
Enrollment: 1,884 participants, actual
Lead sponsor: Duke University
Conditions: Arterial Thromboembolic Events, Atrial Fibrillation
Interventions: Placebo, Dalteparin
First posted: 2008-11-06
Last updated: 2016-03-07
Results first posted: 2016-03-07

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Arterial Thromboembolic Events	from subject signing of the consent until completed the study (Day -30 to Day +37)	The events are defined as arterial thromboembolism: stokes, transient ischemic attack and systemic embolism events were independently and blindly adjudicated
Primary	Major Bleeding	from subject signing of the consent until completed the study (Day -30 to Day +37)	Major bleeding is defined as symptomatic bleeding associated with transfusion of more than two units of packed red blood cells or whole blood, or death
Secondary	Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism	from subject signing of the consent until completed the study (Day -30 to Day +37)
Secondary	Number of Participants With Minor Bleeding	from subject signing of the consent until completed the study (Day -30 to Day +37)	Minor bleeding is defined as symptomatic or clinically-overt bleeding that does not satisfy the criteria for major bleeding

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Arterial Thromboembolic Events	from subject signing of the consent until completed the study (Day -30 to Day +37)	Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.	Arterial thromboembolic events	NUMBER
PRIMARY	Major Bleeding	from subject signing of the consent until completed the study (Day -30 to Day +37)	Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.	participants	NUMBER
SECONDARY	Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism	from subject signing of the consent until completed the study (Day -30 to Day +37)	Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.	participants	NUMBER
SECONDARY	Number of Participants With Minor Bleeding	from subject signing of the consent until completed the study (Day -30 to Day +37)	Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data	participants	NUMBER

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Number of Arterial Thromboembolic Events	Placebo	Stroke	2	Arterial thromboembolic events
Number of Arterial Thromboembolic Events	Dalteparin	Stroke	3	Arterial thromboembolic events
Number of Arterial Thromboembolic Events	Placebo	Transient Ischemic Attack	2	Arterial thromboembolic events
Number of Arterial Thromboembolic Events	Dalteparin	Transient Ischemic Attack	0	Arterial thromboembolic events
Number of Arterial Thromboembolic Events	Placebo	Systemic embolism	0	Arterial thromboembolic events
Number of Arterial Thromboembolic Events	Dalteparin	Systemic embolism	0	Arterial thromboembolic events
Major Bleeding	Placebo		12	participants
Major Bleeding	Dalteparin		29	participants
Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism	Placebo	Death	5	participants
Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism	Dalteparin	Death	4	participants

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	950
Overall Study	STARTED	Dalteparin	934
Overall Study	COMPLETED	Placebo	913
Overall Study	COMPLETED	Dalteparin	891
Overall Study	NOT COMPLETED	Placebo	37
Overall Study	NOT COMPLETED	Dalteparin	43

Source ClinicalTrials.gov

Adverse events244

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
serious	Coagulopathy	Blood and lymphatic system disorders	Placebo	0	950
serious	Coagulopathy	Blood and lymphatic system disorders	Dalteparin	1	934
serious	Hypocoagulable State	Blood and lymphatic system disorders	Placebo	0	950
serious	Hypocoagulable State	Blood and lymphatic system disorders	Dalteparin	1	934
serious	Acute Coronary Syndrome	Cardiac disorders	Placebo	0	950
serious	Acute Coronary Syndrome	Cardiac disorders	Dalteparin	1	934
serious	Acute Myocardial Infarction	Cardiac disorders	Placebo	0	950
serious	Acute Myocardial Infarction	Cardiac disorders	Dalteparin	3	934
serious	Angina Pectoris	Cardiac disorders	Placebo	1	950
serious	Angina Pectoris	Cardiac disorders	Dalteparin	1	934

1 to 10 of 244Source ClinicalTrials.gov

See all 244 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Dalteparin
Total, other adverse events	Placebo	0	0
Total, other adverse events	Dalteparin	0	0
Total, serious adverse events	Placebo	66	950
Total, serious adverse events	Dalteparin	133	934

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
22244711	DERIVED	PubMed
26095867	DERIVED	PubMed
27280017	DERIVED	PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
U01HL086755	BRIDGE TRIAL	HASSELBLAD, VICTOR	DUKE UNIVERSITY	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2008 to 2014	NIH RePORTER
U01HL087229	BRIDGE TRIAL	ORTEL, THOMAS L	DUKE UNIVERSITY	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2008 to 2014	NIH RePORTER

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Dalteparin vs Placebo: Number of Participants With Minor Bleeding	Trial comparisons
Dalteparin vs Placebo: Major Bleeding	Trial comparisons
Dalteparin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00786474

GET https://conductscience.org/api/trials/v1/NCT00786474/events?page=2

API reference For AI assistants